|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Dror Ben-Asher||Co-Founder, Chairman & CEO||442,95k||N/D||1966|
|Mr. Micha Ben-Chorin||Chief Financial Officer||343,66k||N/D||1969|
|Mr. Gilead Raday||Chief Operating Officer||333,07k||N/D||1975|
|Mr. Adi Frish||Sr. VP of Bus. Devel. & Licensing||348,52k||N/D||1970|
|Mr. Guy Goldberg||Chief Bus. Officer||346,14k||N/D||1976|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of clinical late-stage drugs for the treatment of gastrointestinal diseases in the United States. The company commercializes and promotes various gastrointestinal products, including Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS) and acute enterocolitis; EnteraGam, a medical food for the dietary management of chronic diarrhea and loose stools; and Mytesi, an anti-diarrheal drug for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Its principal clinical late-stage development programs include Talicia for the treatment and eradication of Helicobacter pylori infection for which an NDA submitted and accepted for priority review; RHB-104 with positive results from a first Phase 3 study for crohn's disease; RHB-204, a planned pivotal Phase 3 study drug for pulmonary nontuberculous mycobacteria infections; BEKINDA with positive results from a first Phase 3 study for acute gastroenteritis and gastritis, as well as from a Phase 2 study for IBS with diarrhea; YELIVA, a selective inhibitor for multiple oncology, inflammatory, and gastrointestinal indications with an ongoing Phase 2a studies for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation; and RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
L'ISS Governance QualityScore di RedHill Biopharma Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.